We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Janssen Oncology has announced key data on Darzalex (daratumumab) for multiple myeloma at this year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago.